Cargando…

Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis

BACKGROUND: With increasing frequency of resistant Gram-negative bacteria, temocillin has potential utility in reducing carbapenem use. The 2020 EUCAST guideline changes temocillin breakpoints and reclassifies isolates with an MIC of 0.001–16 mg/L as ‘susceptible, increased exposure’ necessitating 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Heard, Katie L, Killington, Kieran, Mughal, Nabeela, Moore, Luke S P, Hughes, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210019/
https://www.ncbi.nlm.nih.gov/pubmed/34223083
http://dx.doi.org/10.1093/jacamr/dlab005
_version_ 1783709230514044928
author Heard, Katie L
Killington, Kieran
Mughal, Nabeela
Moore, Luke S P
Hughes, Stephen
author_facet Heard, Katie L
Killington, Kieran
Mughal, Nabeela
Moore, Luke S P
Hughes, Stephen
author_sort Heard, Katie L
collection PubMed
description BACKGROUND: With increasing frequency of resistant Gram-negative bacteria, temocillin has potential utility in reducing carbapenem use. The 2020 EUCAST guideline changes temocillin breakpoints and reclassifies isolates with an MIC of 0.001–16 mg/L as ‘susceptible, increased exposure’ necessitating 6 g/day rather than the previous 4 g/day, associated with significant cost implications. OBJECTIVES: We explore the clinical utility and treatment failure rate of temocillin at 4 g/day dosing. METHODS: All adult inpatient electronic prescriptions of temocillin (3 days or greater) from March 2016 to October 2019 were retrieved using a clinical decision support system (ICNET(®)). Treatment success was defined as survival, no switch to broad-spectrum agent for the same indication and no subsequent recrudescence of infection, occurring within 30 days. RESULTS: Temocillin was used in 205 eligible patient-episodes, median age 79 years (IQR : 71–87 years), 42.4% female. Median temocillin course length was 5.9 days (IQR : 4.6–7.8 days). Indications for use: urinary tract infection (UTI) (n = 141), pneumonia (n = 53), other (n = 11). In total, 144 (70.2%) patients had targeted treatment; 74 (36.1%) against Escherichia coli, 70 (34.4%) other Enterobacterales. A total of 130 (63%) patients received 4 g/day; the remaining patients had reduced renal function with dosing in accordance with guidance. Overall temocillin treatment success was 79.5%; highest when used to treat UTI 85.8% (versus 67.9% in respiratory infections, P = 0.008). Empirical treatment demonstrated 82.0% (50/61) success [versus 78.5% (113/144) among targeted treatment, P = 0. 71]. CONCLUSIONS: Temocillin at 4 g/day is an effective and safe alternative in treating patients with Gram-negative infections, but should be considered in the context of patient age and comorbidities. Increased dosing or alternate strategies may be indicated when the infection is not of a urinary source.
format Online
Article
Text
id pubmed-8210019
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82100192021-07-02 Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis Heard, Katie L Killington, Kieran Mughal, Nabeela Moore, Luke S P Hughes, Stephen JAC Antimicrob Resist Original Article BACKGROUND: With increasing frequency of resistant Gram-negative bacteria, temocillin has potential utility in reducing carbapenem use. The 2020 EUCAST guideline changes temocillin breakpoints and reclassifies isolates with an MIC of 0.001–16 mg/L as ‘susceptible, increased exposure’ necessitating 6 g/day rather than the previous 4 g/day, associated with significant cost implications. OBJECTIVES: We explore the clinical utility and treatment failure rate of temocillin at 4 g/day dosing. METHODS: All adult inpatient electronic prescriptions of temocillin (3 days or greater) from March 2016 to October 2019 were retrieved using a clinical decision support system (ICNET(®)). Treatment success was defined as survival, no switch to broad-spectrum agent for the same indication and no subsequent recrudescence of infection, occurring within 30 days. RESULTS: Temocillin was used in 205 eligible patient-episodes, median age 79 years (IQR : 71–87 years), 42.4% female. Median temocillin course length was 5.9 days (IQR : 4.6–7.8 days). Indications for use: urinary tract infection (UTI) (n = 141), pneumonia (n = 53), other (n = 11). In total, 144 (70.2%) patients had targeted treatment; 74 (36.1%) against Escherichia coli, 70 (34.4%) other Enterobacterales. A total of 130 (63%) patients received 4 g/day; the remaining patients had reduced renal function with dosing in accordance with guidance. Overall temocillin treatment success was 79.5%; highest when used to treat UTI 85.8% (versus 67.9% in respiratory infections, P = 0.008). Empirical treatment demonstrated 82.0% (50/61) success [versus 78.5% (113/144) among targeted treatment, P = 0. 71]. CONCLUSIONS: Temocillin at 4 g/day is an effective and safe alternative in treating patients with Gram-negative infections, but should be considered in the context of patient age and comorbidities. Increased dosing or alternate strategies may be indicated when the infection is not of a urinary source. Oxford University Press 2021-02-14 /pmc/articles/PMC8210019/ /pubmed/34223083 http://dx.doi.org/10.1093/jacamr/dlab005 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Heard, Katie L
Killington, Kieran
Mughal, Nabeela
Moore, Luke S P
Hughes, Stephen
Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
title Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
title_full Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
title_fullStr Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
title_full_unstemmed Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
title_short Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis
title_sort clinical outcomes of temocillin use for invasive enterobacterales infections: a single-centre retrospective analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210019/
https://www.ncbi.nlm.nih.gov/pubmed/34223083
http://dx.doi.org/10.1093/jacamr/dlab005
work_keys_str_mv AT heardkatiel clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis
AT killingtonkieran clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis
AT mughalnabeela clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis
AT moorelukesp clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis
AT hughesstephen clinicaloutcomesoftemocillinuseforinvasiveenterobacteralesinfectionsasinglecentreretrospectiveanalysis